Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Open access
Siefker-Radtke, Arlene O, Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, O'Hagan, Anne, Loriot, Yohann, Necchi, Andrea, Loriot, Yohann, Park, Se Hoon, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Duran, Ignacio, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, Zakharia, Yousef · 2022 · The Lancet Oncology

Abstract

BACKGROUND Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis of the BLC2001 study at median 11 months of follow-up. We aimed to assess the long-term efficacy and safety of the selected regimen of erdafitinib determined in the initial part of the study. METHODS The open-label, non-comparator, phase 2, BLC2001 study was done at 126 medical centres in 14 countries across Asia, Europe, and North America. Eligible patients were aged 18 years or older with locally advanced and unresectable or metastatic urothelial carcinoma, at least one prespecified FGFR alteration, an Eastern Cooperative Oncology Group performance status of 0-2, and progressive disease after receiving at least one systemic chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy or were ineligible for cisplatin. The selected regimen determined in the initial part of the study was continuous once daily 8 mg/day oral erdafitinib in 28-day cycles, with provision for pharmacodynamically guided uptitration to 9 mg/day (8 mg/day UpT). The primary endpoint was investigator-assessed confirmed objective response rate according to Response Evaluation Criteria In Solid Tumors version 1.1. Efficacy and safety were analysed in all treated patients who received at least one dose of erdafitinib. This is the final analysis of this study. This study is registered with ClinicalTrials.gov, NCT02365597. FINDINGS Between May 25, 2015, and Aug 9, 2018, 2328 patients were screened, of whom 212 were enrolled and 101 were treated with the selected erdafitinib 8 mg/day UpT regimen. The data cutoff date for this analysis was Aug 9, 2019. Median efficacy follow-up was 24·0 months (IQR 22·7-26·6). The investigator-assessed objective response rate for patients treated with the selected erdafitinib regimen was 40 (40%; 95% CI 30-49) of 101 patients. The safety profile remained similar to that in the primary analysis, with no new safety signals reported with longer follow-up. Grade 3-4 treatment-emergent adverse events of any causality occurred in 72 (71%) of 101 patients. The most common grade 3-4 treatment-emergent adverse events of any cause were stomatitis (in 14 [14%] of 101 patients) and hyponatraemia (in 11 [11%]). There were no treatment-related deaths. INTERPRETATION With longer follow-up, treatment with the selected regimen of erdafitinib showed consistent activity and a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations. FUNDING Janssen Research & Development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00660-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 171

Metadata

Authors
Siefker-Radtke, A. O., Necchi, A., Park, S. H., García-Donas, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh Kalebasty, A., Mellado, B., Varlamov, S., Joshi, M., Duran, I., Tagawa, S. T., Zakharia, Y., Akapame, S., Santiago-Walker, A. E., Monga, M., O'Hagan, A., Loriot, Y., Necchi, A., Loriot, Y., Park, S. H., Tagawa, S., Flechon, A., Alexeev, B., Varlamov, S., Huddart, R., Burgess, E., Rezazadeh, A., Siefker-Radtke, A., Vano, Y., Gasparro, D., Hamzaj, A., Kopyltsov, E., Gracia Donas, J., Mellado, B., Parikh, O., Schatteman, P., Culine, S., Houédé, N., Zanetta, S., Facchini, G., Scagliotti, G., Schinzari, G., Lee, J. L., Shkolnik, M., Fleming, M., Joshi, M., O'Donnell, P., Stöger, H., Decaestecker, K., Dirix, L., Machiels, J. P., Borchiellini, D., Delva, R., Rolland, F., Hadaschik, B., Retz, M., Rosenbaum, E., Basso, U., Mosca, A., Lee, H. J., Shin, D. B., Cebotaru, C., Duran, I., Moreno, V., Perez Gracia, J. L., Pinto, A., Su, W.-P., Wang, S.-S., Hainsworth, J., Schnadig, I., Srinivas, S., Vogelzang, N., Loidl, W., Meran, J., Gross Goupil, M., Joly, F., Imkamp, F., Klotz, T., Krege, S., May, M., Schultze-Seemann, W., Strauss, A., Zimmermann, U., Keizman, D., Peer, A., Sella, A., Berardi, R., De Giorgi, U., Sternberg, C. N., Rha, S. Y., Bulat, I., Izmailov, A., Matveev, V., Vladimirov, V., Carles, J., Font, A., Saez, M., Syndikus, I., Tarver, K., Appleman, L., Burke, J., Dawson, N., Jain, S., & Zakharia, Y.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-02
Volume
23
Issue
2
Pages
248-258
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4205486610
Cited by
171
References
3
FWCI
32.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00660-4
The paper
Siefker-Radtke, A. O., Necchi, A., Park, S. H., García-Donas, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh Kalebasty, A., Mellado, B., Varlamov, S., Joshi, M., Duran, I., Tagawa, S. T., Zakharia, Y., Akapame, S., Santiago-Walker, A. E., Monga, M., O'Hagan, A., Loriot, Y., . . . Zakharia, Y. (2022). Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00660-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.